These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 36041291)

  • 21. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
    Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
    BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Gordon SF; Clothier HJ; Morgan H; Buttery JP; Phuong LK; Monagle P; Chunilal S; Wood EM; Tran H; Szer J; Crawford NW;
    Vaccine; 2021 Nov; 39(48):7052-7057. PubMed ID: 34756770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways.
    Kircheis R
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.
    Fang F; Tse B; Pavenski K
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35902184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management.
    Caron P
    Endocrine; 2022 Dec; 78(3):406-417. PubMed ID: 35763241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual.
    Ogai A; Yoshida R; Yuasa C; Chin K; Fujimaki K; Nakajima H
    Int J Hematol; 2022 Feb; 115(2):293-295. PubMed ID: 34716890
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.
    Woolley P; Tailor A; Shah R; Westwood JP; Scully M
    J Thromb Haemost; 2022 Jun; 20(6):1476-1484. PubMed ID: 35313390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
    Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
    JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection.
    Vahabi M; Ghazanfari T; Sepehrnia S
    Int Immunopharmacol; 2022 Nov; 112():109183. PubMed ID: 36182877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into new-onset autoimmune diseases after COVID-19 vaccination.
    Guo M; Liu X; Chen X; Li Q
    Autoimmun Rev; 2023 Jul; 22(7):103340. PubMed ID: 37075917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).
    Parums DV
    Med Sci Monit; 2021 Apr; 27():e932899. PubMed ID: 33900279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report.
    Molina-Rios S; Rojas-Martinez R; Estévez-Ramirez GM; Medina YF
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):43-46. PubMed ID: 35246682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.
    Yousaf AR; Cortese MM; Taylor AW; Broder KR; Oster ME; Wong JM; Guh AY; McCormick DW; Kamidani S; Schlaudecker EP; Edwards KM; Creech CB; Staat MA; Belay ED; Marquez P; Su JR; Salzman MB; Thompson D; Campbell AP;
    Lancet Child Adolesc Health; 2022 May; 6(5):303-312. PubMed ID: 35216660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
    Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Asante KP; Bhate AS; Beresnev T; Bonaparte MI; Celle M; Ceregido MA; Corey L; Dobrianskyi D; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kibuuka H; Koutsoukos M; Masotti R; Michael NL; Neuzil KM; Reynales H; Robb ML; Villagómez Martínez SM; Sawe F; Schuerman L; Tong T; Treanor J; Wartel TA; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
    Lancet Respir Med; 2023 Nov; 11(11):975-990. PubMed ID: 37716365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Immune Thrombocytopenia after COVID-19 Vaccination: Two Case Reports and a Literature Review.
    Shonai T; Kimura F; Watanabe J
    Intern Med; 2022 May; 61(10):1581-1585. PubMed ID: 35314552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases.
    Caza TN; Cassol CA; Messias N; Hannoudi A; Haun RS; Walker PD; May RM; Seipp RM; Betchick EJ; Amin H; Ziadie MS; Haderlie M; Eduwu-Okwuwa J; Vancea I; Seek M; Elashi EB; Shenoy G; Khalillullah S; Flaxenburg JA; Brandt J; Diamond MJ; Frome A; Kim EH; Schlessinger G; Ulozas E; Weatherspoon JL; Hoerschgen ET; Fabian SL; Bae SY; Iqbal B; Chouhan KK; Karam Z; Henry JT; Larsen CP
    Kidney360; 2021 Nov; 2(11):1770-1780. PubMed ID: 35372991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.